58957-91-8

Usage

Uses

Used in Oncology:
Daunorubicin is used as a chemotherapy agent for the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors. It works by interfering with the replication of DNA within cancer cells, ultimately leading to their destruction. Due to its potent anticancer properties, daunorubicin is often used in combination with other chemotherapy drugs to enhance the overall effectiveness of cancer treatment.
Used in Drug Delivery Systems:
To improve the delivery and bioavailability of daunorubicin, various drug delivery systems have been developed. These systems aim to enhance the therapeutic outcomes of daunorubicin by increasing its solubility, stability, and targeted delivery to cancer cells. Examples of drug delivery systems for daunorubicin include liposomes, nanoparticles, and polymeric carriers.
Used in Research:
Daunorubicin is also used as a research tool to study the mechanisms of action of anthracycline antibiotics and their potential applications in cancer therapy. Researchers use daunorubicin to investigate the molecular pathways involved in cancer cell growth and survival, as well as to develop new strategies for overcoming drug resistance in cancer treatment.

InChI:InChI=1/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16+,17-,21+,26+/m0/s1

Upstream product

• 82343-11-1 (-)-4'-O-p-Nitrobenzoyl-N-trifluoroacetyl-4-demethoxydaunorubicin 
• 60660-74-4 (+)-N-Trifluoroacetyl-4-demethoxydaunorubicin 
• 63700-24-3 2,3,6-trideoxy-4-O-(p-nitrobenzoyl)-3-(trifluoroacetamido)-α-L-lyxo-hexopyranosyl p-nitrobenzoate 
• 23541-50-6 daunomycin hydrochloride 
• 874384-80-2 7-(3-azido-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)daunorubicinone 
• 1403987-61-0 4-demethyl-3'-N₃-daunorubicine 
• 1403872-35-4 C₂₇H₂₄F₃N₃O₁₂S 
• 1403872-37-6 4-demethoxy-3'-N₃-daunorubicin 
• 62414-07-7 N-[(2S,3R,4S,6R)-6-((1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy)-3-hydroxy-2-methyl-tetrahydro-pyran-4-yl]-2,2,2-trifluoro-acetamide 
• 60660-75-5 (7S,9S)-idarubicinone 
• 63700-25-4 1-chloro-2,3,6-trideoxy-4-O-p-nitrobenzoyl-3-trifluoroacetamido-L-lyxohexopyranose 
• 60733-79-1 3'-N-trifluoroacetyl-4-demethoxy-7,9-bisepidaunomycin 
• 82343-11-1 4-Nitro-benzoic acid (2S,3R,4S,6R)-6-((1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-naphthacen-1-yloxy)-2-methyl-4-(2,2,2-trifluoro-acetylamino)-tetrahydro-pyran-3-yl ester 
• 128572-89-4 4-Nitro-benzoic acid (2S,3R,4S)-6-chloro-2-methyl-4-(2,2,2-trifluoro-acetylamino)-tetrahydro-pyran-3-yl ester 

Downstream Products

• 57852-57-0 idarubicin hydrochloride 

Relevant academic research and scientific papers

Method of producing 4-demethoxydaunorubicin

The present invention relates to a method for the synthesis of 4-demethoxydaunorubicin (idarubicin) having the chemical structure of formula (I), which involves the demethylation of 3'-Prot-daunorubicin in the presence of a soft Lewis acid. The method of the present invention does not comprise cleavage of the glycosidic linkage at carbon C7, thus resulting in a faster synthesis cycle and an improved yield of the final product.

THERAPEUTIC FOR HEPATIC CANCER

A novel pharmaceutical composition for treating or preventing hepatocellular carcinoma and a method of treatment are provided. A pharmaceutical composition for treating or preventing liver cancer is obtained by combining a chemotherapeutic agent with an anti-glypican 3 antibody. Also disclosed is a pharmaceutical composition for treating or preventing liver cancer which comprises as an active ingredient an anti-glypican 3 antibody for use in combination with a chemotherapeutic agent, or which comprises as an active ingredient a chemotherapeutic agent for use in combination with an anti-glypican 3 antibody. Using the chemotherapeutic agent and the anti-glypican 3 antibody in combination yields better therapeutic effects than using the chemotherapeutic agent alone, and mitigates side effects that arise from liver cancer treatment with the chemotherapeutic agent.

Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same

Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.

TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES

The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the in-vivo release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may be an anticancer agent (or one with other therapeutic properties) carrying a free —NH— which has been derivatized by the attachment of an electrophile containing a moiety, such as p-CN— or p-NO 2-pyridinylsulfonyl groups, or p-NO 2- or 2,4 dinitrophenylsulfonyl groups, or suitable derivatives thereof, to make a prodrug. Optionally, the sulfonamide moiety may have attached to it a targeting molecule. The present invention also provides Glutathione S-transferase (GST)/Reduced Gluthathione (GSH) as a means for the release of a protected amino derivative that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The precursor is a synthetic intermediate carrying a free —NH— which has been derivatized by the attachment of an electrophile via a sulfonamide bond.

Method for identifying an enzyme to design anti-cancer compounds

The present invention relates to a method for identification of enzymes that are preferentially expressed in certain tumor tissue as compared with rapidly growing normal cells or tissue, use of said enzymes for the compound design to generate an active anti-cancer substance selectively in tumor tissue, compounds designed based on said enzymes, their pharmaceutically acceptable salts as well as pharmaceutical composition thereof.

Compositions containing piperine

A pharmaceutical composition having increased bioavailability characterized by piperine of the formula STR1 and a drug for treating a disease or condition of the human cardiovascular system, central nervous system, gastrointestinal tract, respiratory tract, endocrine system, genito urinary tract or haemopoietic system.

Compositions containing piperine

A pharmaceutical composition having increased bioavailability characterized by piperine of the formula and a drug for treating a disease or condition of the human cardiovascular system, central nervous system, gastrointestinal tract, respiratory tract, endocrine system, genito urinary tract or haemopoietic system.

Synthesis and antitumor activity of novel 4-demethoxyanthracyclines

A versatile and efficient synthetic route to 4-demethoxyanthracyclinones has been utilized in the preparation of a number of aglycons having 9-alkyl, 9-(hydroxylalkyl), or 9-carbamoyl substituents. Silver trifluoromethanesulfonate catalyzed coupling of th

Anthracyclines. Part 3. The Total Synthesis of 4-Demethoxydaunomycin

Procedures selected from our earlier work have been applied to the synthesis of (+)-4-demethoxydaunomycinone (10) and (-)-4-demethoxy-7,9-bisepidaunomycinone. 4-Demethoxydaunomycin has been prepared from the (+)-aglycone by specific glycosidation using 1-chloro4-O-p-nitrobenzoyl-3-N-trifluoroacetyldaunosamine and silver trifluoromethanesulphonate as catalyst.Analogous glycosidation of the (-)-aglycone has given 4-demethoxy-7,9-bisepidaunomycin whose properties differ from those previously reported.

Total Synthesis of 4-Demethoxydaunomycin

The Diels-Alder adduct prepared from the optically active, fully functionalised bicyclic precursor (8) and o-benzoquinone dimethide has been converted in good yield inmto (+)-4-demethoxydaunomycinone (13), glycosidation of which with the daunosamine derivative (14) gives 4-demethoxydaunomycin.